Specific gene expressions of host cells by spontaneous STAT6 phosphorylation are major strategy for the survival of intracellular Toxoplasma gondii against parasiticidal events through STAT1 phosphorylation by infection provoked IFN-γ. We determined the effects of small molecules of tyrosine kinase inhibitors (TKIs) on the growth of T. gondii and on the relationship with STAT1 and STAT6 phosphorylation in ARPE-19 cells. We counted the number of T. gondii RH tachyzoites per parasitophorous vacuolar membrane (PVM) after treatment with TKIs at 12-hr intervals for 72 hr. The change of STAT6 phosphorylation was assessed via western blot and immunofluorescence assay. Among the tested TKIs, Afatinib (pan ErbB/EGFR inhibitor, 5 ?M) inhibited 98.0% of the growth of T. gondii, which was comparable to pyrimethamine (5 ?M) at 96.9% and followed by Erlotinib (ErbB1/EGFR inhibitor, 20 ?M) at 33.8% and Sunitinib (PDGFR or c-Kit inhibitor, 10 ?M) at 21.3%. In the early stage of the infection (2, 4, and 8 hr after T. gondii challenge), Afatinib inhibited the phosphorylation of STAT6 in western blot and immunofluorescence assay. Both JAK1 and JAK3, the upper hierarchical kinases of cytokine signaling, were strongly phosphorylated at 2 hr and then disappeared entirely after 4 hr. Some TKIs, especially the EGFR inhibitors, might play an important role in the inhibition of intracellular replication of T. gondii through the inhibition of the direct phosphorylation of STAT6 by T. gondii.
Citations
Citations to this article as recorded by
Small molecule kinase inhibitor altiratinib inhibits brain cyst forming bradyzoites of Toxoplasma gondii Yeong Hoon Kim, Hye-Jin Ahn, Hwa Sun Kim, Ho-Woo Nam Journal of Microbiology.2025; 63(2): e2409001. CrossRef
iTRAQ-Based Phosphoproteomic Analysis Exposes Molecular Changes in the Small Intestinal Epithelia of Cats after Toxoplasma gondii Infection Bintao Zhai, Yu-Meng Meng, Shi-Chen Xie, Jun-Jie Peng, Yang Liu, Yanhua Qiu, Lu Wang, Jiyu Zhang, Jun-Jun He Animals.2023; 13(22): 3537. CrossRef
Secretome Analysis of Host Cells Infected with Toxoplasma gondii after Treatment of Human Epidermal Growth Factor Receptor 2/4 Inhibitors Hye-Jung Kim, Hye-Jin Ahn, Hyeweon Kang, Jaehui Park, Seul gi Oh, Saehae Choi, Won-Kyu Lee, Ho-Woo Nam The Korean Journal of Parasitology.2020; 58(3): 249. CrossRef
A Human Proteome Array Approach to Identifying Key Host Proteins Targeted by Toxoplasma Kinase ROP18 Zhaoshou Yang, Yongheng Hou, Taofang Hao, Hee-Sool Rho, Jun Wan, Yizhao Luan, Xin Gao, Jianping Yao, Aihua Pan, Zhi Xie, Jiang Qian, Wanqin Liao, Heng Zhu, Xingwang Zhou Molecular & Cellular Proteomics.2017; 16(3): 469. CrossRef
Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review Ruben R. Ben-Harari, Elizabeth Goodwin, Julio Casoy Drugs in R&D.2017; 17(4): 523. CrossRef
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells Yeong Hoon Kim, Lokraj Bhatt, Hye-Jin Ahn, Zhaoshou Yang, Won-Kyu Lee, Ho-Woo Nam The Korean Journal of Parasitology.2017; 55(5): 491. CrossRef
Toxoplasma gondii is the causative agent of toxoplasmosis with symptoms of congenital neurological and ocular diseases and acquired lymphadenitis, retinochoroiditis, and meningoencephalitis. Small molecules which block the activity of protein kinases were tested in in vitro culture of T. gondii to find new therapeutic drugs of safer and more effective than the combined administration of pyrimethamine and sulfadoxine that sometimes provoke lethal Stevens-Johnson syndrome. Among them, Gefitinib and Crizotinib inhibited intracellular growth of T. gondii in HeLa cells by counting the number of T. gondii per parasitophorous vacuolar membrane whereas Sunitinib did not. Gefitinib inhibited the growth of T. gondii in a dose-dependent manner over 5 ?M up to the tolerable concentration of HeLa cells and halted the division of the parasite immediately from the time point of treatment. Gefitinib inhibition suggests that tyrosine kinases of EGFR family or other homologous kinases of the parasite itself may be the target to cause the block of T. gondii growth.
Citations
Citations to this article as recorded by
Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024) Hassan Aliashrafzadeh, Dewey Liu, Samantha De Alba, Imad Akbar, Austin Lui, Jordan Vanleuven, Ryan Martin, Zhang Wang, Da Zhi Liu Exploration of Drug Science.2025;[Epub] CrossRef
The antimicrobial activity of innate host-directed therapies: A systematic review Tirosh Shapira, Matthew Christofferson, Yossef Av-Gay International Journal of Antimicrobial Agents.2024; 63(5): 107138. CrossRef
Impact of Training Data, Ground Truth and Shape Variability in the Deep Learning-Based Semantic Segmentation of HeLa Cells Observed with Electron Microscopy Cefa Karabağ, Mauricio Alberto Ortega-Ruíz, Constantino Carlos Reyes-Aldasoro Journal of Imaging.2023; 9(3): 59. CrossRef
Role of EtMIC4 EGF-like in regulating the apoptosis of Eimeria tenella host cells via the EGFR pathway Xue-song Zhang, Yong-juan Zhao, Yu Zhang, Tong Xu, Kai-ling Cui, Bu-ting Duan, Xiao-ling Lv, Li Zhang, Zhi-yong Xu, Rui Bai, Ming-xue Zheng Poultry Science.2022; 101(10): 102075. CrossRef
FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders Austin Lui, Jordan Vanleuven, David Perekopskiy, Dewey Liu, Desiree Xu, Omar Alzayat, Taiseer Elgokhy, Timothy Do, Meghan Gann, Ryan Martin, Da-Zhi Liu Pharmaceuticals.2022; 15(12): 1546. CrossRef
Clearing or subverting the enemy: Role of autophagy in protozoan infections George Ghartey-Kwansah, Benjamin Aboagye, Frank Adu-Nti, Yeboah Kwaku Opoku, Emmanuel Kwasi Abu Life Sciences.2020; 247: 117453. CrossRef
Secretome Analysis of Host Cells Infected with Toxoplasma gondii after Treatment of Human Epidermal Growth Factor Receptor 2/4 Inhibitors Hye-Jung Kim, Hye-Jin Ahn, Hyeweon Kang, Jaehui Park, Seul gi Oh, Saehae Choi, Won-Kyu Lee, Ho-Woo Nam The Korean Journal of Parasitology.2020; 58(3): 249. CrossRef
Autophagy in the control and pathogenesis of parasitic infections George Ghartey-Kwansah, Frank Adu-Nti, Benjamin Aboagye, Amandus Ankobil, Edward Eyipe Essuman, Yeboah Kwaku Opoku, Samuel Abokyi, Emmanuel Kwasi Abu, Johnson Nyarko Boampong Cell & Bioscience.2020;[Epub] CrossRef
Interplay Between Toxoplasma gondii, Autophagy, and Autophagy Proteins Carlos S. Subauste Frontiers in Cellular and Infection Microbiology.2019;[Epub] CrossRef
The Interplay of Host Autophagy and Eukaryotic Pathogens Robert J. Evans, Varadharajan Sundaramurthy, Eva-Maria Frickel Frontiers in Cell and Developmental Biology.2018;[Epub] CrossRef
A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006–2016) Mahbobeh Montazeri, Mehdi Sharif, Shahabeddin Sarvi, Saeed Mehrzadi, Ehsan Ahmadpour, Ahmad Daryani Frontiers in Microbiology.2017;[Epub] CrossRef
The Toxoplasma Parasitophorous Vacuole: An Evolving Host–Parasite Frontier Barbara Clough, Eva-Maria Frickel Trends in Parasitology.2017; 33(6): 473. CrossRef
Activation of a Neospora caninum EGFR-Like Kinase Facilitates Intracellular Parasite Proliferation Xiaoxia Jin, Guojiang Li, Xichen Zhang, Pengtao Gong, Yanhui Yu, Jianhua Li Frontiers in Microbiology.2017;[Epub] CrossRef
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells Yeong Hoon Kim, Lokraj Bhatt, Hye-Jin Ahn, Zhaoshou Yang, Won-Kyu Lee, Ho-Woo Nam The Korean Journal of Parasitology.2017; 55(5): 491. CrossRef
Human toxoplasmosis–Searching for novel chemotherapeutics Magdalena Antczak, Katarzyna Dzitko, Henryka Długońska Biomedicine & Pharmacotherapy.2016; 82: 677. CrossRef
Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity Andrew J. Neville, Sydney J. Zach, Xiaofang Wang, Joshua J. Larson, Abigail K. Judge, Lisa A. Davis, Jonathan L. Vennerstrom, Paul H. Davis Antimicrobial Agents and Chemotherapy.2015; 59(12): 7161. CrossRef
First
Prev
